DNA gyrase inhibitors - Pipeline Insight, 2022
This report can be delivered to the clients within 48 hours
DelveInsight’s, “DNA gyrase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 12+ companies and 13+ pipeline drugs in DNA gyrase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
DNA gyrase inhibitors: Overview
DNA gyrase is classified as topoisomerase II, an ATP-dependent enzyme. The enzymes plays vital role in transcription, replication of DNA and chromosome segregation processes in all bacteria except higher eukaryotes. Escherichia coli DNA gyrase is composed of two subunits, A and B. The active gyrase is a heterotetramer (A2B2). The GyrA N-terminal domain contains the site for DNA breakage and reunion while the C-terminal domain has a DNA wrapping function. The ability of DNA gyrase to introduce negative supercoils into DNA is a unique feature amongst all known type II topoisomerases. Therefore, this enzyme is desirable therapeutic target for development of new antibacterial agents.
Report Highlights
This segment of the DNA gyrase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
DNA gyrase inhibitors Emerging Drugs
Further product details are provided in the report……..
DNA gyrase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different DNA gyrase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
DNA gyrase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses DNA gyrase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging DNA gyrase inhibitors drugs.
DNA gyrase inhibitors Report Insights
Current Scenario and Emerging Therapies:
DelveInsight’s, “DNA gyrase inhibitors - Pipeline Insight, 2022” report provides comprehensive insights about 12+ companies and 13+ pipeline drugs in DNA gyrase inhibitors pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
DNA gyrase inhibitors: Overview
DNA gyrase is classified as topoisomerase II, an ATP-dependent enzyme. The enzymes plays vital role in transcription, replication of DNA and chromosome segregation processes in all bacteria except higher eukaryotes. Escherichia coli DNA gyrase is composed of two subunits, A and B. The active gyrase is a heterotetramer (A2B2). The GyrA N-terminal domain contains the site for DNA breakage and reunion while the C-terminal domain has a DNA wrapping function. The ability of DNA gyrase to introduce negative supercoils into DNA is a unique feature amongst all known type II topoisomerases. Therefore, this enzyme is desirable therapeutic target for development of new antibacterial agents.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence DNA gyrase inhibitors R&D. The therapies under development are focused on novel approaches for DNA gyrase inhibitors.
This segment of the DNA gyrase inhibitors report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
DNA gyrase inhibitors Emerging Drugs
- TNP 2092: TenNor Therapeutics
- Zoliflodacin: Entasis Therapeutics
Further product details are provided in the report……..
DNA gyrase inhibitors: Therapeutic Assessment
This segment of the report provides insights about the different DNA gyrase inhibitors drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players working on DNA gyrase inhibitors
- Phases
- Late-stage products (Phase III and
- Mid-stage products (Phase II and
- Early-stage products (Phase I/II and Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Infusion
- Intradermal
- Intramuscular
- Intranasal
- Intravaginal
- Oral
- Parenteral
- Subcutaneous
- Topical
- Molecule Type
- Vaccines
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Product Type
DNA gyrase inhibitors: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses DNA gyrase inhibitors therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging DNA gyrase inhibitors drugs.
DNA gyrase inhibitors Report Insights
- DNA gyrase inhibitors Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Scenario and Emerging Therapies:
- How many companies are developing DNA gyrase inhibitors drugs?
- How many DNA gyrase inhibitors drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for DNA gyrase inhibitors?
- What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the DNA gyrase inhibitors therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for DNA gyrase inhibitors and their status?
- What are the key designations that have been granted to the emerging drugs?
- Entasis Therapeutics
- MerLion Pharmaceuticals
- TenNor Therapeutics
- Spero Therapeutics
- NeuroSense Therapeutics
- PolyActiva
- Ocumension Therapeutics
- Microbiotix
- Zoliflodacin
- Finafloxacin
- TNP 2092
- SPR 720
- Celecoxib/ciprofloxacin
- Endophthalmitis preventive implant
- Moxifloxacin/dexamethasone
- SPR-719
- Research programme: antibacterials
Introduction
Executive Summary
DNA gyrase inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
DNA gyrase inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Zoliflodacin: Entasis Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
TNP 2092: TenNor Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Endophthalmitis preventive implant: PolyActiva
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
SPR-719: Spero Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
DNA gyrase inhibitors Key Companies
DNA gyrase inhibitors Key Products
DNA gyrase inhibitors- Unmet Needs
DNA gyrase inhibitors- Market Drivers and Barriers
DNA gyrase inhibitors- Future Perspectives and Conclusion
DNA gyrase inhibitors Analyst Views
DNA gyrase inhibitors Key Companies
Appendix
Executive Summary
DNA gyrase inhibitors: Overview
Structure
Mechanism of Action
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
DNA gyrase inhibitors – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Zoliflodacin: Entasis Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
TNP 2092: TenNor Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
Endophthalmitis preventive implant: PolyActiva
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Pre-clinical and Discovery Stage Products
Comparative Analysis
SPR-719: Spero Therapeutics
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
DNA gyrase inhibitors Key Companies
DNA gyrase inhibitors Key Products
DNA gyrase inhibitors- Unmet Needs
DNA gyrase inhibitors- Market Drivers and Barriers
DNA gyrase inhibitors- Future Perspectives and Conclusion
DNA gyrase inhibitors Analyst Views
DNA gyrase inhibitors Key Companies
Appendix